ID   UROtsa As#6
AC   CVCL_LM64
SY   UT As #6
DR   Wikidata; Q54991822
RX   PubMed=20186695;
RX   PubMed=26783756;
RX   PubMed=30550540;
CC   Characteristics: Tumorigenic derivative of UROtsa. Subcutaneous injection of this cell line in nude mice produces tumors.
CC   Doubling time: 21.6 +- 1.6 hours (PubMed=20186695).
CC   Transformant: ChEBI; CHEBI_29678; Sodium arsenite.
CC   Transformant: NCBI_TaxID; 1891767; Simian virus 40 (SV40).
CC   Derived from site: In situ; Urinary bladder, urothelium; UBERON=UBERON_0004645.
CC   Cell type: Urothelial cell; CL=CL_0000731.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   12Y
CA   Transformed cell line
DT   Created: 15-11-17; Last updated: 19-12-24; Version: 8
//
RX   PubMed=20186695; DOI=10.1002/jat.1513; PMCID=PMC3100548;
RA   Cao L., Zhou X.-D., Sens M.A., Garrett S.H., Zheng Y., Dunlevy J.R.,
RA   Sens D.A., Somji S.;
RT   "Keratin 6 expression correlates to areas of squamous differentiation
RT   in multiple independent isolates of As(+3)-induced bladder cancer.";
RL   J. Appl. Toxicol. 30:416-430(2010).
//
RX   PubMed=26783756; DOI=10.1371/journal.pone.0147362; PMCID=PMC4718619;
RA   Slusser-Nore A., Larson-Casey J.L., Zhang R.-W., Zhou X.-D., Somji S.,
RA   Garrett S.H., Sens D.A., Dunlevy J.R.;
RT   "SPARC expression is selectively suppressed in tumor initiating
RT   urospheres isolated from As+3- and Cd+2-transformed human urothelial
RT   cells (UROtsa) stably transfected with SPARC.";
RL   PLoS ONE 11:e0147362.1-e0147362.22(2016).
//
RX   PubMed=30550540; DOI=10.1371/journal.pone.0207877; PMCID=PMC6294394;
RA   Hoggarth Z.E., Osowski D.B., Freeberg B.A., Garrett S.H., Sens D.A.,
RA   Sens M.A., Zhou X.-D., Zhang K.K., Somji S.;
RT   "The urothelial cell line UROtsa transformed by arsenite and cadmium
RT   display basal characteristics associated with muscle invasive
RT   urothelial cancers.";
RL   PLoS ONE 13:e0207877.1-e0207877.26(2018).
//